Multiple sclerosis is the most common cause of chronic neurological disability in young adults in developed countries and seems to be increasing in frequency.
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Disease presentation in 80-90% of patients follows an initial phase characterised by bouts of relapsingremitting neurological dysfunction. 3 These relapses are thought to represent focal areas of infl ammation in the CNS, and arise with unpredictable frequency and variable recovery. 4 However, after an inconsistent interval, most patients then develop a progressive disease course, with a gradual development of disability in the absence of relapses. The later disease phase accounts for most of the permanent disability and is thought to be mediated by neurodegenerative processes including axonal degeneration. 5 Although some controversy remains regarding the rate at which conversion to secondary progressive multiple sclerosis takes place, a fi gure of 2-3% per year with age-related infl uences is widely accepted. 6 The overall eff ect, in a disorder whose duration exceeds 30 years, is that most patients will, at some stage, develop secondary progressive multiple sclerosis, and at any one time most prevalent patients are in a disease phase for which there is no eff ective treatment.
Initial therapeutic advances targeted the early infl ammatory disease phase, with several licensed immunomodulatory treatments emerging. Treatments available to clinicians for management of relapsingremitting multiple sclerosis are now substantial. Available drugs all have an eff ect on relapse frequency, reduction of brain MRI lesion formation, and can reduce permanent disability when defi ned as worsening with no reversal in 3-6 months. However, the pattern of rising severity and frequency of serious adverse events with increasing drug effi cacy needs careful patient selection, clinical management, and surveillance. Despite these limitations, early and eff ective intervention for relapsing-remitting multiple sclerosis is hoped to have the long-te rm outcome of delaying or abolishing the progressive phase. Nevertheless, evidence for the long-term outcome of early intervention has so far been elusive and, although a much debated treatment strategy, a reluctance to administer powerful immunomodulators at onset, in a disease which can have a highly variable outcome, 7 has made quantifi cation of the eff ect of early aggressive immunomodulatory treatment on long-term outcome diffi cult. No licensed drugs have shown a convincing eff ect on long-term disability, or specifi cally on progressive disease.
Although identifi cation of interventions that have a signifi cant eff ect in modifi cation of physical disability in progressive disease is a main aspiration of clinical trials of multiple sclerosis, an obstacle will be the large numbers of patients needed to achieve adequate power when conventional measures of disability are used. Indeed, this challenge might have contributed to negative results in trials of progressive disease to date, 8 and more accurate contemporary power calculations are needed to inform future studies that aim to report disability as the primary outcome measure. As a result, eff ective alternative measures to identify promising drugs in phase 2 studies are needed before large-scale investments in larger trials are considered.
In multiple sclerosis, measurement of brain atrophy has been recognised as a plausible surrogate outcome for disability, 9, 10 and some studies of immunomodulatory drugs have shown an eff ect on reducing this outcome. Further support for the use of change in brain volume in this context has also emerged in an analysis of treatment in relapsing multiple sclerosis that showed a correlation of treatment eff ect on brain atrophy with the eff ect on disability (r²=0·48). 11 However, the association with eff ect on disability was greater with use of MRI lesion activity (r²=0·61) and greater still when both MRI outcomes were combined (r²=0·75).
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Modifying disability in progressive multiple sclerosis 11 In The Lancet, Jeremy Chataway and colleagues 12 have pursued repurposed drugs with relevant and plausible mechanisms of action by studying the eff ects of simvastatin 80 mg per day in 140 patients with secondary progressive multiple sclerosis in a phase 2, placebocontrolled randomised trial. This drug was selected for its potential anti-infl ammatory and neuroprotective properties. Mean annualised atrophy rate was signifi cantly lower in patients in the simvastatin group (0·288% per year [SD 0·521]) than in those in the placebo group (0·584% per year [0·498]) with an adjusted diff erence of −0·254% per year (95% CI −0·422 to −0·087; p=0·003); a 43% reduction in annualised rate. Furthermore, lower disability scores were reported for two of three measures after 2 years of simvastatin compared with placebo. Although sustained disability was not reported, a signifi cant diff erence was noted in favour of simvastatin in the mean 2-year Expanded Disability Scale Status (EDSS) score (diff erence −0·254, 95% CI −0·464 to −0·069) and the Multiple Sclerosis Impact Scale-29 (−4·78, −9·39 to −0·02; adjusted for respective baselines). Of note, the reported eff ect on these outcomes, presumed to be relevant to neurodegenerative processes, was not accompanied by signifi cant eff ects on infl ammatory outcomes such as relapse, MRI brain lesions, or serum immunological markers, which could suggest a primary neuroprotective role for simvastatin. Only two previous randomised trials (one single-blind) 13, 14 have presented neuroprotective effi cacy data that seem to be independent of anti-infl ammatory eff ects, and both were in patients with relapsing-remitting multiple sclerosis.
Chataway and colleagues' study is a promising and novel development. The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred. This form of multiple sclerosis has been largely neglected by a pharmaceutical industry that has so far focused on the early infl ammatory processes. A substantial advantage of this study is the fairly low cost, availability, and documented safety profi le of the drug. The study also reports a predominant eff ect on neurodegenerative rather than infl ammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments.
Caution in interpretation of these preliminary data is, however, needed. Patients with relapsing secondary progressive multiple sclerosis were not excluded, which might have aff ected results, although frequency of relapses was not reduced in the face of a reduction in 2-year disability. The expected eff ects of simvastin on infl ammation were also not shown. Furthermore, the disability outcome was a surrogate measure and not the usual outcome used in phase 3 trials. This fi nding is relevant because single disability measures show great variability in the short term, 15 and the trial was clearly underpowered to identify an eff ect on arguably the least sensitive of disability measures (EDSS). The meaning of an eff ect on atrophy, without a reduction in lesion activity, in predicting the future eff ect on sustained disability outcomes is unknown. Further phase 3 studies to measure the eff ect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease.
In the SPRING-2 1 trial, dolutegravir showed noninferiority to raltegravir, another integrase inhibitor, in antiretroviral-naive adults with HIV-1 infection. In the SINGLE trial, 2 dolutegravir showed superiority over a non-nucleoside reverse transcriptase inhibitor, efavirenz. The next obvious step of the dolutegravir targeted strategy was to compare dolutegravir with a boosted protease inhibitor such as darunavir plus ritonavir. The comparison between dolutegravir and a boosted protease inhibitor is particularly interesting because boosted protease inhibitors are very potent and, by contrast with raltegravir and efavirenz, 3 extremely resilien t to HIV resistance development even when used as monotherapy. 4 In The Lancet, Bonaventura Clotet and colleagues present the FLAMINGO study, 5 in which 484 antiretroviralnaive HIV-infected patients were randomly assigned to receive two nucleos(t)ide reverse transcriptase inhibitors (tenofovir-emtricitabine or abacavir-lamivudine) plus either dolutegravir (50 mg) or the boosted protease inhibitor darunavir (800 mg) plus ritonavir (100 mg). After 48 weeks of follow-up, more than 80% of patients in each group achieved virological suppression (217 [90%] patients receiving dolutegravir and 200 [83%] patients receiving darunavir plus ritonavir had HIV-1 RNA of less than 50 copies per mL, adjusted diff erence 7·1% [95% CI 0·9-13·2]), and no patient developed drug resistance. It is diffi cult to imagine a better outcome for a clinical trial in a disease that just two decades ago did not have an eff ective treatment.
In a prespecifi ed secondary analysis, dolutegravir also showed superiority to darunavir plus ritonavir. The data suggest that superiority was driven both by better tolerability (nine [3%] patients in the dolutegravir group and 20 [9%] patients in the darunavir plus ritonavir group discontinued for non-virological reasons) and better effi cacy (virological success in 217 [90%] patients in the dolutegravir group vs 200 [83%] patients in the darunavir plus ritonavir group), especially in the 25% of patients who started with viral loads greater than 100 000 copies per mL. But is dolutegravir really superior to darunavir plus ritonavir? This is a diffi cult question to answer for various reasons.
First, FLAMINGO 5 is an open-label clinical trial with two pills a day taken by patients in the dolutegravir group versus four pills a day taken by those in the comparator group (darunavir plus ritonavir). The openlabel design might have led to patients, disappointed with their treatment assignment, choosing not to continue. In fact, six patients withdrew in the darunavir plus ritonavir group very early on compared with the one patient who withdrew in the dolutegravir group. 
